The goal of most current vaccines in tumor immunology is to induce an efficient immune response against the tumor cells. The use of red blood cells (RBCs) for the delivery of tumor-associated antigen to antigen-presenting cells is an innovative approach for cancer immunotherapy. The induction of antigen-specific immune responses after administration of antigen-loaded RBCs has been demonstrated previously in mice. In this paper, we show the utility of this delivery system for cancer immunotherapy in 2 tumor mouse models, using the E.G7-OVA and the B16F10 tumor cells. The non-self-antigen, ovalbumin, loaded in RBCs and the self-tumor antigen, tyrosinase-related protein 2, loaded in RBCs were tested in the E.G7-OVA and the B16F10 tumor models, respectively. We showed that not only protein but also peptide could be efficiently entrapped in RBCs by a controlled lysis/resealing process. In both antigen models, the administration of a small quantity of antigen loaded in RBCs combined with polyinosinic-polycytidylic acid induced an antigen-specific T-cell response and the control of tumor growth in mice, whereas the injection of the same quantity of free antigen did not. The intensity of the T-cell response was dependent on the concentrations of antigen entrapped and the treatment performed on the RBC membrane (antibody coating and heat treatment) to improve antigen delivery. In summary, these results support the use of RBCs as an antigen delivery system for a powerful cancer immunotherapy approach.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/CJI.0b013e3182594352 | DOI Listing |
Immunology
January 2025
Singapore Immunology Network (SIgN), A*STAR, Singapore, Singapore.
Cancer is one of the leading causes of death worldwide. In recent years, immune checkpoint inhibitor therapies, in addition to standard immuno- or chemotherapy and surgical approaches, have massively improved the outcome for cancer patients. However, these therapies have their limitations and improved strategies, including access to reliable cancer vaccines, are needed.
View Article and Find Full Text PDFHum Vaccin Immunother
December 2025
Department of Thyroid and Breast Surgery, Jining NO. 1 People' Hospital, Jining, China.
This bibliometric and visualization study provides a comprehensive analysis of global research hotspots and trends in DNA vaccine research from 2014 to 2024. By employing data sourced from the Web of Science Core Collection, we identified a total of 3,600 articles. Our analysis reveals a declining trend in annual publications.
View Article and Find Full Text PDFNano Lett
January 2025
Department of Physics, Shahid Beheshti University, Tehran 1635649771, Iran.
We present a method for conjugating antigens to gold nanoparticles (GNPs) during their synthesis via gas plasma, eliminating the need for chemical linkers and significantly speeding up the process (taking only 15 min). This fast, linker-free method produces biocompatible and stable GNPs, with potential for immunotherapy applications, such as antigen and antibody conjugation and drug delivery. We demonstrate the conjugation of the antigen Nestin (NES), a tumor marker, to GNPs using two approaches.
View Article and Find Full Text PDFBioact Mater
April 2025
School of Life Sciences and Health Engineering, Jiangnan University, Wuxi, 214122, PR China.
Peptide vaccines based on tumor antigens face the challenges of rapid clearance of peptides, low immunogenicity, and immune suppressive tumor microenvironment. However, the traditional solution mainly uses exogenous substances as adjuvants or carriers to enhance innate immune responses, but excessive inflammation can damage adaptive immunity. In the current study, we propose a straightforward novel nanovaccine strategy by employing homologous human ferritin light chain for minimized innate immunity and dendritic cell (DC) targeting, the cationic KALA peptide for enhanced cellular uptake, and suppressor of cytokine signaling 1 (SOCS1) siRNA for modulating DC activity.
View Article and Find Full Text PDFCurr Drug Deliv
January 2025
Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya (A Central University of M.P.), Sagar, Madhya Pradesh, 470003, India.
In recent years, there have been notable strides in developing mRNA vaccines, resulting in the creation of potent immunizations against diverse diseases. This review examines the most recent advancements in this field, focusing on their implications for future vaccine development. The pursuit of heightened vaccine efficacy is investigated through cutting-edge methods in adjuvant selection, delivery system optimization, and antigen selection.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!